Navigation Links
Medigene Appointed Exclusive Greek Licensee for GeneMedRx Personalized Prescribing Software

SEATTLE and ATHENS, Greece, July 9 /PRNewswire/ -- The companies jointly announce the appointment of Medigene as the exclusive licensee and translator of the Greek language version of the GeneMedRx drug and gene interaction software program. When localization is complete the program will include hundreds of drugs used exclusively in Greece, thousands of translated interaction notes and a Greek language graphical user interface. Both the English and Greek versions of GeneMedRx rely on a sophisticated, artificial intelligence algorithm to analyze complex medication regimens and DNA test results to identify interactions that can lead to treatment failure and adverse side effects.

"We're delighted to be working with someone as knowledgeable and visionary as Dr. Papacharisis. He and his team are ideally placed to expand the usefulness of this important product and to bring it to Greece and the wider European market," stated Howard Coleman, Genelex CEO. Following the launch of the software in Greece it is anticipated that other language versions will be jointly developed and sold throughout Europe.

"GeneMedRx is a uniquely powerful product that has the potential to greatly improve patient care because it detects many more problematic drug interactions than competing products. We're extremely pleased to be bringing the benefits of this comprehensive personalized medication management tool to our country," stated George Papacharisis, Medigene founder. Dr. Papacharisis' team plans to develop the GeneMedRx algorithm for the point-of-sale safety scanning of pharmaceuticals.

Medigene is a new company founded by George Papacharisis, noted author and pharmacist, and a team of pharmacy software experts. Medigene is bringing the benefits of GeneMedRx Personalized Prescribing to physicians, patients and pharmacies in Greece.

Genelex (jen-uh-LEX) sells DNA Drug Sensitivity testing and the GeneMedRx (jeen-med-r-x) software to doctors to help them choose the safest medicines for their patients. The company's long term plan is to scale up the software to integrate with hand-held devices and e-prescribing programs so that all adverse drug reaction software is "Powered by GeneMedRx." Widespread use of these tools represents a major opportunity to save lives, improve patient outcomes and save billions of healthcare dollars every year.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Howard Coleman

SOURCE Genelex
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. David Feldman, M.D. Appointed Co-Principal Investigator of DuraHeart(TM) Left Ventricular Assist System U.S. Clinical Trial
2. Autism Spectrum Therapies Co-Founder and Chief Clinical Officer Dr. William Frea Appointed to Board of Directors of Los Angeles Chapter of Autism Speaks
3. Wound Management Technologies Completes Acquisition of Secure eHealth, LLC and Other Assets from VirtualHealth Technologies; Robert Tapales Appointed President of Secure eHealth, LLC
4. VirtualHealth Technologies Completes Sale of Secure eHealth, LLC and Other Assets to Wound Management Technologies; Robert Tapales Appointed President of Secure eHealth, LLC
5. Clive Dix Appointed as Chairman of Crescendo Biologics
6. Ruediger Naumann-Etienne Appointed to IRIDEX Board of Directors
7. Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger
8. Pharmaceutical Industry Veteran is Appointed CMO at Kinex Pharmaceuticals
9. Charles E. Lannon Was Appointed as Vice-Chairman of the Board of Directors at Kinex Pharmaceuticals
10. Michael W. Marine Appointed CEO of Sabin Vaccine Institute
11. Veteran International Health Care Executive Appointed CEO of BeneChill(R)
Post Your Comments:
(Date:11/25/2015)... 2015 Kitov Pharma ceuticals ... a biopharmaceutical company focused on the development of therapeutic ... today announced the closing of its previously announced underwritten ... ), each representing 20 ordinary shares of the Company, ... ADSs and warrants were issued in a fixed combination ...
(Date:11/25/2015)...  Today AVACEN Medical announced the issue of United States patent No. ... ". This patent shields the company,s AVACEN 100 dry heat therapy medical device and specific methods ... Photo - ... ... ...
(Date:11/25/2015)... , Nov. 25, 2015 USP 800 ... drug preparations (e.g. pharmacists, pharmacy technicians, nurses, physicians, ... technicians). The chapter also covers all entities which ... pharmacies, hospitals, other healthcare institutions, patient treatment clinics, ... --> --> What is ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert ... Organizations, One Beat ” campaign. The partnership between the two groups began in 2014 ... MAP International’s cause. , MAP International was founded in 1954 and is an international ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug rehabilitation ... new cutting edge recovery program that has been 50 years in the making. ... with the purpose to free addicts from the symptoms and negative behaviors of addiction. ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for ... aware of the benefits of Botox® in the treatment of moderate facial wrinkling, few ... and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted by an ... IL, UV Angel is evaluating the efficacy of its product and its disinfection protocol. ... 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic medical ...
(Date:11/25/2015)... Spring, Md (PRWEB) , ... November 25, 2015 ... ... Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible ... history of this disease. The Periwinkle Pioneers, nominated by the public, will receive ...
Breaking Medicine News(10 mins):